Pharsight

Dsuvia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778393 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US9320710 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8535714 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8778394 ACELRX PHARMS Small-volume oral transmucosal dosage forms
Jan, 2027

(3 years from now)

US10342762 ACELRX PHARMS Small-volume oral transmucosal dosage forms
Jan, 2027

(3 years from now)

US8231900 ACELRX PHARMS Small-volume oral transmucosal dosage
Jan, 2027

(3 years from now)

US8252328 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(3 years from now)

US9744129 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8252329 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(3 years from now)

US8226978 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8865211 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(3 years from now)

US10245228 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US10507180 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US10896751 ACELRX PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(6 years from now)

US8574189 ACELRX PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(6 years from now)

US8865743 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Oct, 2030

(7 years from now)

US8202535 ACELRX PHARMS Small-volume oral transmucosal dosage forms
Oct, 2030

(7 years from now)

US8945592 ACELRX PHARMS Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Jul, 2031

(7 years from now)

Dsuvia is owned by Acelrx Pharms.

Dsuvia contains Sufentanil Citrate.

Dsuvia has a total of 18 drug patents out of which 0 drug patents have expired.

Dsuvia was authorised for market use on 02 November, 2018.

Dsuvia is available in tablet;sublingual dosage forms.

Dsuvia can be used as treatment of acute pain.

The generics of Dsuvia are possible to be released after 29 July, 2031.

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

DSUVIA family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11676691 VERTICAL PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(6 years from now)

US11672738 VERTICAL PHARMS Apparatus and methods for dispensing oral transmucosal dosage forms
Feb, 2038

(14 years from now)

Dsuvia is owned by Vertical Pharms.

Dsuvia contains Sufentanil Citrate.

Dsuvia has a total of 2 drug patents out of which 0 drug patents have expired.

Dsuvia was authorised for market use on 02 November, 2018.

Dsuvia is available in tablet;sublingual dosage forms.

The generics of Dsuvia are possible to be released after 02 February, 2038.

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

DSUVIA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic